C G Willett

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. doi request reprint Chemoradiotherapy in gastrointestinal malignancies
    C G Willett
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Clin Oncol (R Coll Radiol) 21:543-56. 2009
  2. pmc Preoperative chemoradiotherapy for locally advanced gastric cancer
    Joseph M Pepek
    Department of Radiation Oncology, Duke University School of Medicine, Box 3085, Durham, NC 27710, USA
    Radiat Oncol 8:6. 2013
  3. doi request reprint Compliance with therapeutic guidelines in Radiation Therapy Oncology Group prospective gastrointestinal clinical trials
    Christopher G Willett
    Duke University, Durham, United States
    Radiother Oncol 105:9-13. 2012
  4. pmc Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study
    Christopher G Willett
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 27:3020-6. 2009
  5. ncbi request reprint Radiation therapy in stage II and III rectal cancer
    Christopher G Willett
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Clin Cancer Res 13:6903s-8s. 2007
  6. pmc Targeted therapy in rectal cancer
    Christopher G Willett
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27705, USA
    Oncology (Williston Park) 21:1055-65; discussion 1065, 1070, 1075 passim. 2007
  7. pmc A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer
    Christopher G Willett
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Oncologist 15:845-51. 2010
  8. ncbi request reprint Adjuvant therapy of pancreatic cancer
    Christopher G Willett
    Department of Radiation Oncology and Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC 27705, USA
    Cancer J 13:185-91. 2007
  9. pmc Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer
    Christopher G Willett
    Duke University Medical Center, Durham, NC 27710, USA
    Nat Clin Pract Oncol 4:316-21. 2007
  10. ncbi request reprint Intraoperative radiation therapy
    Christopher G Willett
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 25:971-7. 2007

Detail Information

Publications79

  1. doi request reprint Chemoradiotherapy in gastrointestinal malignancies
    C G Willett
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Clin Oncol (R Coll Radiol) 21:543-56. 2009
    ..This overview highlights current results, controversies and potential future directions in the chemoradiotherapeutic treatment of selected gastrointestinal malignancies...
  2. pmc Preoperative chemoradiotherapy for locally advanced gastric cancer
    Joseph M Pepek
    Department of Radiation Oncology, Duke University School of Medicine, Box 3085, Durham, NC 27710, USA
    Radiat Oncol 8:6. 2013
    ..To examine toxicity and outcomes for patients treated with preoperative chemoradiotherapy (CRT) for gastric cancer...
  3. doi request reprint Compliance with therapeutic guidelines in Radiation Therapy Oncology Group prospective gastrointestinal clinical trials
    Christopher G Willett
    Duke University, Durham, United States
    Radiother Oncol 105:9-13. 2012
    ..We aim to provide insight into current standards and compliance of radiation therapy field design and administration...
  4. pmc Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study
    Christopher G Willett
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 27:3020-6. 2009
    ..To assess the safety and efficacy of neoadjuvant bevacizumab with standard chemoradiotherapy in locally advanced rectal cancer and explore biomarkers for response...
  5. ncbi request reprint Radiation therapy in stage II and III rectal cancer
    Christopher G Willett
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Clin Cancer Res 13:6903s-8s. 2007
    ..Current phase III studies are evaluating novel combinations of chemotherapy and targeted agents with radiation therapy...
  6. pmc Targeted therapy in rectal cancer
    Christopher G Willett
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27705, USA
    Oncology (Williston Park) 21:1055-65; discussion 1065, 1070, 1075 passim. 2007
    ..This review will address completed and ongoing trials that have established and continue to clarify the effects of these agents in rectal cancer...
  7. pmc A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer
    Christopher G Willett
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Oncologist 15:845-51. 2010
    ..As a benchmark, we used data from an analysis of 42 patients with locally advanced rectal cancer treated with a contemporary approach of preoperative fluoropyrimidine-based radiation therapy...
  8. ncbi request reprint Adjuvant therapy of pancreatic cancer
    Christopher G Willett
    Department of Radiation Oncology and Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC 27705, USA
    Cancer J 13:185-91. 2007
    ..Phase III trials evaluating these modalities have led to conflicting results, leading to controversy in the use and selection of therapy. Phase II studies are now being conducted to evaluate target agent therapy with chemoradiation...
  9. pmc Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer
    Christopher G Willett
    Duke University Medical Center, Durham, NC 27710, USA
    Nat Clin Pract Oncol 4:316-21. 2007
    ..The case presented here is a complete pathological response seen in a patient with extensive and locally invasive carcinoma after receiving this combined treatment...
  10. ncbi request reprint Intraoperative radiation therapy
    Christopher G Willett
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 25:971-7. 2007
    ..Optimally, phase III randomized trials will be carried out to prove its efficacy in these disease sites...
  11. pmc Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411
    Christopher H Crane
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 27:4096-102. 2009
    ..Secondary end points were toxicity, progression-free survival (PFS), and response rate (RR)...
  12. ncbi request reprint Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer
    Kevin S Roof
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 65:1120-8. 2006
    ..This article updates our experience with PFT-R, and compares these results to our experience with cisplatin, 5-FU, and radiation therapy (PF-R) in locally advanced esophageal cancer...
  13. ncbi request reprint Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer
    K Lindel
    Department of Radiation Oncology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Radiother Oncol 58:83-7. 2001
    ..CONCLUSION: The current analysis shows the importance of a microscopic complete resection in a multi-modality approach with IORT for survival and local control. Salvage is rare for patients undergoing subtotal resection...
  14. doi request reprint Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial
    William F Regine
    Department of Radiation Oncology, University of Maryland Medical Center, Baltimore 21030, USA
    JAMA 299:1019-26. 2008
    ..Among patients with locally advanced metastatic pancreatic adenocarcinoma, gemcitabine has been shown to improve outcomes compared with fluorouracil...
  15. ncbi request reprint Combined modality therapy for rectal and colon cancer
    Ashish K Chawla
    Department of Radiation Oncology, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114, USA
    Semin Oncol 30:101-12. 2003
    ..Active areas of investigation in CMT for colorectal cancer include the integration of biologic predictors, radiation modulators, and novel systemic agents...
  16. ncbi request reprint Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials
    Christopher G Willett
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 56:31-7. 2003
    ..This report summarizes current and future Radiation Therapy Oncology Group clinical trials in the treatment of patients with localized pancreatic cancer...
  17. ncbi request reprint Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study
    L R Coia
    Department of Radiation Oncology, Community Medical Center, Toms River, NJ 08755, USA
    J Clin Oncol 18:455-62. 2000
    ....
  18. ncbi request reprint Radiation therapy in the management of rectal cancer
    L A Kachnic
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Curr Opin Oncol 13:300-6. 2001
    ..The incorporation of improved radiation planning may reduce treatment-related bowel toxicity. The integration of novel chemotherapeutic agents in the adjuvant therapy of rectal cancer remains an active area of investigation...
  19. ncbi request reprint A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma
    Brian G Czito
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 70:1066-72. 2008
    ..We evaluated the safety and preliminary efficacy of a combination of UFT/leucovorin, carboplatin, and paclitaxel with RT in a Phase I study of patients with advanced esophageal cancer...
  20. ncbi request reprint Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy
    Chris R Kelsey
    Department of Radiation Oncology, Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 69:1436-41. 2007
    ..To report patterns of disease recurrence after resection of adenocarcinoma of the duodenum and compare outcomes between patients undergoing surgery only vs. surgery with concurrent chemotherapy and radiation therapy (CT-RT)...
  21. ncbi request reprint Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results
    Brian G Czito
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 68:472-8. 2007
    ..A Phase I trial was undertaken to evaluate the combination of bevacizumab, capecitabine, oxaliplatin, and radiation therapy in patients with rectal cancer...
  22. doi request reprint Emerging role of intensity-modulated radiation therapy in anorectal cancer
    Jeffrey J Meyer
    Department of Radiation Oncology, Duke University Medical Center, DUMC Box 3085, Durham, NC 27710, USA
    Expert Rev Anticancer Ther 8:585-93. 2008
    ..This article reviews the rationale for its use in treating anorectal tumors and discusses early clinical data supporting its continued investigation...
  23. ncbi request reprint Reduction of organ motion by combined cardiac gating and respiratory gating
    Zhiheng Wang
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 68:259-66. 2007
    ..To investigate whether the effect of organ motion can be further reduced with the application of a cardiac gating technique, together with respiratory gating...
  24. ncbi request reprint Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer
    Chris R Kelsey
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 69:770-6. 2007
    ..To compare a neoadjuvant regimen of cisplatin/5-fluorouracil (5-FU) and concurrent radiation therapy (RT) with paclitaxel-based regimens and RT in the management of operable esophageal (EC)/gastroesophageal junction (GEJ) cancer...
  25. pmc Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer
    Dan G Duda
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Oncologist 15:577-83. 2010
    ..Based on the findings in this exploratory study, we propose that plasma sVEGFR-1 should be further studied as a potential biomarker to stratify patients in future studies of bevacizumab and/or cytotoxics in the neoadjuvant setting...
  26. ncbi request reprint Combined-modality therapy for rectal cancer: future prospects
    Brian G Czito
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Clin Colorectal Cancer 6:625-33. 2007
    ..These agents are now being studied with radiation therapy in the neoadjuvant therapy of rectal cancer...
  27. doi request reprint Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis
    Joseph M Pepek
    Department of Radiation Oncology, Duke University School of Medicine, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 78:1413-9. 2010
    ..Intensity-modulated radiation therapy (IMRT) has the potential to reduce toxicities associated with chemoradiotherapy in the treatment of anal cancer. This study reports the results of using IMRT in the treatment of anal cancer...
  28. ncbi request reprint The impact of advanced technologies on treatment deviations in radiation treatment delivery
    Lawrence B Marks
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 69:1579-86. 2007
    ..To assess the impact of new technologies on deviation rates in radiation therapy (RT)...
  29. ncbi request reprint Commentary: rectal cancer an evolution of treatment
    Brian G Czito
    Radiation Oncology Clinical Support, Box 3085 Med Ctr, Durham, North Carolina 27710, USA
    Oncologist 12:1319-20. 2007
  30. ncbi request reprint Integration of cone-beam CT in stereotactic body radiation therapy
    Fang Fang Yin
    Department of Radiation Oncology, Duke University Medical Center, Durham NC, USA
    Technol Cancer Res Treat 7:133-9. 2008
    ..Improved immobilization may enhance positioning accuracy. Typical total "in-room" times for the patients are approximately 1 hour. CBCT-guided SBRT is feasible and enhances setup accuracy using 3-D anatomical information...
  31. ncbi request reprint Current management of anal canal cancer
    Brian G Czito
    Department of Radiation Oncology, Box 3085, Duke University Medical Center, Durham, NC 27710, USA
    Curr Oncol Rep 11:186-92. 2009
    ..Other studies are evaluating the use of capecitabine, oxaliplatin, and the anti-epidermal growth factor receptor agent cetuximab with RT in this malignancy...
  32. ncbi request reprint Radiation therapy advances for treatment of anal cancer
    Joseph M Pepek
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Natl Compr Canc Netw 8:123-9. 2010
    ..This article reviews the basic principles of IMRT and highlights current literature on these recent advances and the application of new RT techniques...
  33. ncbi request reprint Intensity-modulated radiation therapy for anal cancer
    Brian G Czito
    Department of Radiation Oncology, Duke University, School of Medicine, Durham, North Carolina, USA
    Oncology (Williston Park) 23:1082-9. 2009
    ....
  34. pmc Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer
    Lei Xu
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer Res 69:7905-10. 2009
    ..These data show that VEGF blockade up-regulates inflammatory pathways and NRP1, which should be evaluated as potential targets for improving anti-VEGF therapy...
  35. ncbi request reprint Quantification of respiration-induced abdominal tumor motion and its impact on IMRT dose distributions
    David P Gierga
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 58:1584-95. 2004
    ..The motion of tumors in the abdomen was studied using quantitative fluoroscopic analysis, and the effect on dose delivery to the target was studied...
  36. ncbi request reprint Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience
    Brian G Czito
    Department of Radiation Oncology, Duke University Medical Center, Box 3085, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 62:1030-4. 2005
    ..To better define the role of adjuvant radiation therapy and chemotherapy, a retrospective analysis of the outcome of patients undergoing surgery and adjuvant therapy was undertaken...
  37. ncbi request reprint Update on combined-modality treatment options for pancreatic cancer
    Christopher G Willett
    Harvard Medical School, Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncology (Williston Park) 17:29-36. 2003
    ....
  38. ncbi request reprint Locally advanced pancreatic cancer
    Christopher G Willett
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 23:4538-44. 2005
    ..These treatments include external-beam irradiation with and without fluorouracil-based chemotherapy, intraoperative irradiation, and, more recently, external-beam irradiation with new systemic targeted agents...
  39. pmc Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
    Christopher G Willett
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Nat Med 10:145-7. 2004
    ..These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors...
  40. ncbi request reprint Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results
    Brian G Czito
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 24:656-62. 2006
    ..We initiated two phase I trials assessing the combination of gefitinib, capecitabine, and radiation in patients with localized pancreatic and rectal cancer...
  41. pmc Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer
    Christopher G Willett
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Ann Surg 241:295-9. 2005
    ..To analyze the effects of a treatment program of intraoperative electron beam radiation therapy (IOERT) and external beam radiation therapy and chemotherapy on the outcome of patients with unresectable or locally advanced pancreatic cancer...
  42. pmc Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers
    Dan G Duda
    Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 25:4033-42. 2007
    ..Finally, we offer a perspective on future research directions aimed at making this complex therapeutic approach successful in the clinic...
  43. ncbi request reprint Is radiation therapy required for patients with intermediate-risk rectal cancer?
    Harvey Mamon
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Adv Hematol Oncol 5:638-44, 585. 2007
    ..Current data permit identification of these patients, but no randomized studies have yet demonstrated that selected patients with locally advanced rectal cancer can safely be spared adjuvant or neoadjuvant radiation...
  44. ncbi request reprint Intensity-modulated radiation therapy for anal cancer: toxicity versus outcomes
    Timothy M Zagar
    Department of Radiation Oncology, Duke University School of Medicine, Durham, North Carolina 27705, USA
    Oncology (Williston Park) 24:815-23, 828. 2010
    ..This article reviews the relevant literature leading up to the modern treatment of anal canal cancer, and discusses IMRT-related toxicity and disease-related outcomes in the context of outcomes of conventionally treated anal cancer...
  45. ncbi request reprint The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996-1999 Patterns of Care Study
    Mohan Suntharalingam
    Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Int J Radiat Oncol Biol Phys 56:981-7. 2003
    ..This study examined the evaluation and treatment schemes used during this time and compared these results to the PCS data obtained between 1992 and 1994 to identify any fundamental changes in national practice...
  46. ncbi request reprint Palliative treatment of rectal cancer: is radiotherapy alone a good option?
    Christopher G Willett
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Gastrointest Surg 8:277-9. 2004
  47. pmc Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice
    Christopher G Willett
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Semin Oncol 33:S35-40. 2006
    ..Phase II evaluation of bevacizumab in this setting is under way...
  48. doi request reprint Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma
    John W Nelson
    Department of Radiation Oncology, Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC, USA
    Int J Radiat Oncol Biol Phys 73:148-53. 2009
    ..To clarify the role of radiotherapy with chemotherapy, we performed a retrospective analysis of resected patients who had undergone chemoradiotherapy...
  49. ncbi request reprint Intraoperative radiation therapy
    C G Willett
    Department of Radiation Oncology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Int J Clin Oncol 6:209-14. 2001
    ..The future of IORT will be in the successful integration of this therapy into multimodality treatment programs of chemotherapy, external beam irradiation, and surgery for locally advanced malignancies...
  50. pmc Biomarkers of response and resistance to antiangiogenic therapy
    Rakesh K Jain
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
    Nat Rev Clin Oncol 6:327-38. 2009
    ....
  51. pmc Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas
    Robert J Myerson
    Department of Radiation Oncology, Washington University, St Louis, MO, USA
    Int J Radiat Oncol Biol Phys 74:824-30. 2009
    ..To develop a Radiation Therapy Oncology Group (RTOG) atlas of the elective clinical target volume (CTV) definitions to be used for planning pelvic intensity-modulated radiotherapy (IMRT) for anal and rectal cancers...
  52. ncbi request reprint The correlation between internal and external markers for abdominal tumors: implications for respiratory gating
    David P Gierga
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 61:1551-8. 2005
    ..Data of this type are important for image-guided therapy techniques, such as respiratory gating, that monitor the movement of external fiducials...
  53. ncbi request reprint Clinical physics, applicator choice, technique, and equipment for electron intraoperative radiation therapy
    Peter J Biggs
    Department of Radiation Oncology, Massachusetts General Hospital, Fruit Street, Boston, MA 02114, USA
    Surg Oncol Clin N Am 12:899-924. 2003
    ..There are currently six new centers in the United States that practice IORT with a mobile linear accelerator and more than that in Europe...
  54. ncbi request reprint Results of radiation therapy in gastric cancer
    Christopher G Willett
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Semin Radiat Oncol 12:170-5. 2002
    ..Ongoing trials are now investigating new systemic agents with radiation therapy to establish efficacy compared to 5-FU and LV, as well as evaluating neoadjuvant approaches prior to resection...
  55. pmc VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects
    Dan G Duda
    Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, COX 734, Boston, MA 02114, USA
    Trends Mol Med 13:223-30. 2007
    ....
  56. ncbi request reprint Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms
    C G Willett
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 46:995-8. 2000
    ..To clarify the use of this modality in this setting, this study assesses the short- and long-term tolerance of 28 patients with IBD to abdominal and pelvic irradiation...
  57. ncbi request reprint Advances in combined radiation therapy for the management of rectal cancer
    Lisa A Kachnic
    Department of Radiation Oncology, Boston Medical Center, Boston University School of Medicine, MA 02118, USA
    Expert Rev Anticancer Ther 3:471-83. 2003
    ....
  58. ncbi request reprint Radiation therapy for resectable colon cancer. Is there a role in the modern chemotherapy era?
    Brian G Czito
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Oncology (Williston Park) 20:179-87; discussion 187-8, 192. 2006
    ..Adjuvant radiation therapy should be considered in patients with colon cancer at high risk for local failure...
  59. ncbi request reprint Radiation therapy in the treatment of cholangiocarcinoma
    Brian G Czito
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Oncology (Williston Park) 20:873-84; discussion 886-8, 893-5. 2006
    ..Although these new approaches hold promise, the prognosis in patients with biliary cancers remains poor, and the integration of novel therapeutic strategies is indicated...
  60. doi request reprint Nonoperative management of rectal cancer: current perspectives
    Kristin A Higgins
    Department of Radiation Oncology Duke, University Medical Center, Durham, NC 27710, USA
    Clin Colorectal Cancer 9:83-8. 2010
    ..This comprehensive review summarizes the current literature regarding the nonoperative management of rectal cancer and discusses caveats and controversies to such an approach...
  61. ncbi request reprint Management of locally advanced adenocarcinoma of the pancreas
    David P Ryan
    Gastrointestinal Cancer Center, Massachusetts General Hospital, Harvard Medical School, Cox 640, 100 Blossom Street, Boston, MA 02114, USA
    Hematol Oncol Clin North Am 16:95-103. 2002
    ..The introduction of gemcitabine into chemoradiotherapy regimens may provide additional improvements in the management of patients. Preoperative therapy has proved feasible but has not shown improvement in overall survival...
  62. ncbi request reprint Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 22:166-74. 2004
    ..However, because these studies often lack detailed information on tumor and treatment characteristics as well as cancer recurrence, the true nature of this relation remains uncertain...
  63. ncbi request reprint Radiation dose escalation in combined-modality therapy for esophageal cancer
    Christopher G Willett
    J Clin Oncol 20:1151-3. 2002
  64. ncbi request reprint Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer
    Andrew X Zhu
    Massachusetts General Hospital, Dana Farber Partners Cancer Care, Harvard Medical School, Boston, MA, USA
    Semin Radiat Oncol 13:454-68. 2003
    ..In this review, we will discuss the mechanism of action and the key clinical studies of each agent as a radiosensitizer...
  65. ncbi request reprint Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients
    Christopher G Willett
    J Clin Oncol 23:8136-9. 2005
  66. pmc Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 26:4551-6. 2008
    ..The primary end point was to assess whether any approach would achieve a >or= 77.5% 1-year survival rate, surpassing the historical 66% rate from the Radiation Therapy Oncology Group (RTOG) protocol 9405...
  67. ncbi request reprint Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiation
    Michael Y Choi
    Int J Radiat Oncol Biol Phys 68:1584. 2007
  68. ncbi request reprint Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations
    Jennifer F Tseng
    Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    Pancreatology 5:67-74. 2005
    ..We sought to determine whether patients undergoing postresection or primary medical treatment for pancreatic adenocarcinoma were immunocompetent...
  69. ncbi request reprint Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer
    David P Kelsen
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:3719-25. 2007
    ..The relationship between resection type and between tumor response and outcome were also analyzed...
  70. ncbi request reprint A challenge to the therapeutic nihilism of ESPAC-1
    Mary C Koshy
    Int J Radiat Oncol Biol Phys 61:965-6. 2005
  71. ncbi request reprint Case records of the Massachusetts General Hospital. Case 20-2005. A 58-year-old man with locally advanced pancreatic cancer
    David P Ryan
    Department of Hematology and Oncology, Massachusetts General Hospital, Boston, USA
    N Engl J Med 352:2734-41. 2005
  72. ncbi request reprint Combined modality treatment for rectal cancer
    Andrew X Zhu
    Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Semin Oncol 32:103-12. 2005
    ..Although 5-fluorouracil (5-FU)-based chemotherapy in combination with RT remains the standard adjuvant therapy for rectal cancer, the integration of novel chemotherapeutic agents and biologic modulators is being actively investigated...
  73. ncbi request reprint Adjuvant therapy for pancreatic cancer: an evolving paradigm
    Andrew X Zhu
    Department of Hematology Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, 100 Blossom Street, Cox 640, Boston, MA 02114, USA
    Surg Oncol Clin N Am 13:605-20, viii. 2004
    ..This review highlights historic and current perspectives of adjuvant therapy in resected pancreatic cancer...
  74. ncbi request reprint Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130
    James A Martenson
    North Central Cancer Treatment Group, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 22:3277-83. 2004
    ..Some patients with colon cancer have a high risk of local recurrence postoperatively. This trial was undertaken to determine whether radiation therapy added to an adjuvant chemotherapy regimen improves outcome in high-risk patients...
  75. ncbi request reprint Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 18-2004. A 61-year-old man with rectal bleeding and a 2-cm mass in the rectum
    Paul C Shellito
    Department of Surgery, Massachusetts General Hospital, USA
    N Engl J Med 350:2500-9. 2004
  76. ncbi request reprint Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis
    Leonard L Gunderson
    Radiation Oncology Department, Mayo Clinic Cancer Center, Scottsdale, AZ 85259, USA
    J Clin Oncol 22:1785-96. 2004
    ..To determine survival and relapse rates by T and N stage and treatment method in five randomized phase III North American rectal adjuvant studies...
  77. ncbi request reprint New approaches to assessing and treating early-stage colon and rectal cancer: summary statement from 2007 Santa Monica Conference
    Lee S Rosen
    Premiere Oncology, Santa Monica, CA 90404, USA
    Clin Cancer Res 13:6853s-6s. 2007
    ....
  78. pmc Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy
    Dan G Duda
    Steele Laboratory for Tumor Biology, Department of Radiation Oncology and Center for Regenerative Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Oncol 24:1449-53. 2006
    ..CD146 is considered a panendothelial-specific marker, but its utility as a CEC marker in cancer patients remains unclear...
  79. ncbi request reprint Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations
    Dushyant V Sahani
    Division of Abdominal Imaging and Intervention, Department of Radiology, Massachusetts General Hospital, 55 Fruit St, White 270 F, Boston, MA 02114, USA
    Radiology 234:785-92. 2005
    ....